Last updated 2 months ago
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
1250 patients around the world
Available in Puerto Rico, Argentina, Mexico, United States
Eli Lilly and Company
21Research sites
1250Patients around the world
This study is for people with
Diabetes
Diabetes mellitus type 2
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have Type 2 Diabetes (T2D)Have HbA1c ≥ 7.0% (53 millimoles per mole (mmol/mol)) to ≤ 10.5% (91 mmol/mol)Have been on a stable diabetes treatment consisting of metformin ≥ 1500 milligrams per day (mg/day) with or without SGLT2i during 90 days prior to screeningAre of stable weight for at least 90 days prior to screeningHave a Body Mass Index (BMI) ≥ 25.0 kilograms per meter squared (kg/m^2)
- Have Type 1 Diabetes (T1D)Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screeningHave a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screeningAre currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edemaHave an estimated glomerular filtration rate (eGFR) <45 milliliters/minute/1.73 meter squared (mL/min/1.73 m^2) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratoryHave a prior or planned surgical treatment for obesityHave New York Heart Association Functional Classification IV congestive heart failureHave had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screeningHave a known clinically significant gastric emptying abnormalityHave a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 yearsHave any lifetime history of a suicide attemptHad chronic or acute pancreatitisHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening
Sites
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Recruiting
Centro Médico Viamonte SRL - CABA, Buenos Aires
Recruiting
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Centro Médico Maffei - CABA, Buenos Aires
Recruiting
STAT Research - CABA
Recruiting
Centro de Alergia y Enfermedades Respiratorias - Buenos Aires
Recruiting
Centro Médico Privado San Vicente Diabetes - Córdoba
Recruiting
Centro de Investigaciones Clínicas Baigorria
Recruiting
Fundación Respirar
Recruiting
Centro Diabetológico Córdoba Dr. Waitman
Recruiting
SponsorEli Lilly and Company
Conditions
Diabetes mellitus type 2
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06260722
